Axcella Health Inc. (NASDAQ:AXLA – Get Rating) – Stock analysts at SVB Leerink increased their Q3 2022 earnings estimates for shares of Axcella Health in a research note issued on Tuesday, August 2nd. SVB Leerink analyst T. Smith now expects that the company will post earnings of ($0.39) per share for the quarter, up from their prior forecast of ($0.40). SVB Leerink has a “Outperform” rating and a $6.00 price objective on the stock. The consensus estimate for Axcella Health’s current full-year earnings is ($1.52) per share. SVB Leerink also issued estimates for Axcella Health’s Q4 2022 earnings at ($0.38) EPS, FY2022 earnings at ($1.58) EPS, FY2023 earnings at ($1.35) EPS, FY2024 earnings at ($1.28) EPS, FY2025 earnings at ($1.46) EPS and FY2026 earnings at ($1.31) EPS.
Several other research analysts have also recently weighed in on AXLA. Wedbush decreased their price target on shares of Axcella Health to $7.00 in a report on Friday, May 27th. HC Wainwright decreased their price target on shares of Axcella Health from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Chardan Capital decreased their price target on shares of Axcella Health from $12.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, May 9th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $6.50.
Axcella Health Trading Down 2.0 %
Axcella Health (NASDAQ:AXLA – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08).
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AXLA. Pinnacle Private Wealth LLC purchased a new position in Axcella Health in the fourth quarter worth $43,000. Edgewood Management LLC boosted its position in Axcella Health by 33.3% during the first quarter. Edgewood Management LLC now owns 100,000 shares of the company’s stock valued at $257,000 after buying an additional 25,000 shares during the period. HarbourVest Partners LLC boosted its position in Axcella Health by 55.9% during the first quarter. HarbourVest Partners LLC now owns 4,378,661 shares of the company’s stock valued at $11,253,000 after buying an additional 1,570,680 shares during the period. Finally, Flagship Pioneering Inc. boosted its position in Axcella Health by 50.4% during the first quarter. Flagship Pioneering Inc. now owns 18,867,785 shares of the company’s stock valued at $48,490,000 after buying an additional 6,319,371 shares during the period. 61.84% of the stock is currently owned by hedge funds and other institutional investors.
About Axcella Health
Axcella Health Inc operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients.
- Get a free copy of the StockNews.com research report on Axcella Health (AXLA)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.